To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Hybrigenics Participates in the MASTERSWITCH European Project
Read time: Less than a minute
Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced that it has signed a substantial contract as part of a large-scale European Union research project called MASTERSWITCH.
Hybrigenics will deploy its protein interaction expertise in the field of chronic inflammatory diseases. The company will develop a high throughput assay and screen its diverse 100,000 compound library and its collection of about 2,000 natural substances. The aim is to identify small-molecule inhibitors of a therapeutically relevant protein interaction.
A hit-to-lead optimization program will then be conducted in close collaboration with Dr. Frederique Ponchel (Leeds Institute of Molecular Medicine, UK) and Prof. Richard Aspinall (Translational Medicine, Cranfield University, UK).
Hybrigenics will receive more than EUR 400,000 over the first two years of the five year-long consortium agreement. "This EU contract is the recognition at international level of the excellence of Hybrigenics' expertise in this area of protein interaction assay development and screening," said Remi Delansorne, CEO at Hybrigenics.
Hybrigenics will deploy its protein interaction expertise in the field of chronic inflammatory diseases. The company will develop a high throughput assay and screen its diverse 100,000 compound library and its collection of about 2,000 natural substances. The aim is to identify small-molecule inhibitors of a therapeutically relevant protein interaction.
A hit-to-lead optimization program will then be conducted in close collaboration with Dr. Frederique Ponchel (Leeds Institute of Molecular Medicine, UK) and Prof. Richard Aspinall (Translational Medicine, Cranfield University, UK).
Hybrigenics will receive more than EUR 400,000 over the first two years of the five year-long consortium agreement. "This EU contract is the recognition at international level of the excellence of Hybrigenics' expertise in this area of protein interaction assay development and screening," said Remi Delansorne, CEO at Hybrigenics.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
